Login to Your Account

Vivus Investors Not Vexed by Qnexa Rejection; Shares Soar

By Donna Young

Monday, November 1, 2010
WASHINGTON – While an FDA complete response letter (CRL) is generally bad luck for most companies, the one Vivus Inc. received for its experimental weight-loss drug Qnexa (phentermine/topiramate) failed to spook investors Friday. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription